,,Good morning tada,,we can respectfully agree to disagree on this one. The past trial failures must be taken into account of course to have a perspective. We do know the apabetalone/covid relationship was pointed out to the team by a 3rd party. Oops,,and the inclusion of stroke in our infamous flop on the BoM trial. We have shifted our focus from reverse transport of colestrol to an antiinflammatory drug platform. Continually in flux trying to find something, anything, which apabetalone has a significant effect on. So far the jury is out on all counts even with the 3 point mace under our belt. The share price is key as the market is very aware of the company's failure/s. We are looked upon as dead money as we stagnate in 5 to 7 year lows in real time because of the lack of solid advancement. Of all the business models out there which are possible this team cant see our future out any farther than the end of their noses. The large shareholders here clearly are no sharper around investing than ourselves. Dreaming of what could be, not what will be! And with a CEO who is completely disconnected from the inner workings of the company ,,,how else could the market react to us! We need a management team with a progressive business plan accepting partners and advancing the list of molecules in wait and not only our one horse show here. ...Jmo.